WIPRO
10.3.2021 15:32:07 CET | Business Wire | Pressemeddelelse
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), en førende global virksomhed inden for informationsteknologi, konsulentvirksomhed og forretningsprocesser annoncerede i dag udnævnelsen af Pierre Bruno som administrerende direktør, Europa.
I denne rolle vil Bruno lede Wipro’s forretning i seks forskellige regioner på tværs af Europa. Denne udnævnelse, er en dristig indikation af virksomhedens fortsatte investering og fokus på det europæiske marked, som bygger på Wipros fremdrift i hele regionen i de seneste år.
“Pierre har mere end 25 års erfaring inden for IT-infrastruktur, konsulent og servicesektoren. Han har leder virksomheder i både hypervækstmiljøer og inden for teknologi transformation. Med hans erfaring i ledelse af store teams er han godt positioneret til at føre Wipros vækstrejse videre i Europa,” sagde Thierry Delaporte, CEO & MD, Wipro Limited.
“Jeg er begejstret for muligheden for at lede Wipro’s aktiviteter på det europæiske marked, der byder på fantastiske muligheder for vækst. Jeg ser frem til at videreudvikle samt fremme vores engagement over for vores europæiske kunder, når de navigerer i deres forretningstransformation og fortsætter med at udvikle sig i en digital verden,” sagde Pierre Bruno , Administrerende direktør, Europa .
Bruno kommer til Wipro fra DXC Technology, hvor han var vicepræsident og administrerende direktør for Sydeuropa, ansvarlig for alle dele af forretningen, herunder rådgivning, integration, apps, cloud og cybersikkerhed. Bruno arbejdede også for Dell i 14 år i flere roller i Asien, Stillehavsområdet, Japan og EMEA. Han spillede en central rolle i Dells transformation fra at sælge hardware til at blive en vigtig aktør inden for levering af infrastrukturløsninger.
Bruno har en kandidatgrad i forretningsadministration (MBA) med hovedfag i Marketing og økonometri fra HEC Graduate School i Paris. Han har også en kandidatgrad i bioteknik.
Wipro’s forpligtelse i Europa
Wipro’s europæiske tilstedeværelse omfatter seks regioner, bestående af Storbritannien og Irland, Tyskland, Schweiz, Norden, Benelux og Sydeuropa, samt tre near-shore leverancecentre og omfatter en bred vifte af betydelige kunder på tværs af brancher, hvoraf mange bliver supporteret af Wipro på deres teknologiste vækst samt transformationsrejse..
Nogle af de seneste aftaler i Europa omfatter
- En vigtig strategisk digital og IT-partnerskabsaftale med METRO AG, en førende global grossistvirksomhed.
- Et engagement med den Finland-baserede producent af ren energi Fortum for at hjælpe med at opgradere applikationslandskabet samt tilhørende serviceintegration,.
- En flerårig global aftale om automotive engineering services med den italienske bilgigant Marelli.
- I Tyskland arbejder vi sammen med Telefónica Germany/O2 og dets bredere økosystem til at transformere deres forretningssupportsystemer og tilhørende kvalitetssikring for at sikre en optimal kundeoplevelse og vækst i B2B-markedssegmentet.
- En strategisk, flerårig infrastruktur’s modernisering og digital transformations services fra det tyskbaserede energiselskab E.ON.
Om Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) er en førende global virksomhed inden for informationsteknologi, rådgivning og forretningsprocesser. Vi udnytter styrken af kognitive computing, hyper-automatisering, robotteknologi, cloud , analytics og nye teknologier til at hjælpe vores kunder med at tilpasse sig den digitale verden og gøre successfulde. En virksomhed, der er anerkendt globalt for sin omfattende portefølje af services, stærkt engagement i bæredygtighed samt virksomhedsetik , vi har over 190.000 dedikerede medarbejdere, der betjener vores kunder på seks kontinenter. Sammen kommer vi med nye ideer samt udvikler og skaber en bedre og dristig ny fremtid.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov
. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210310005602/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum